63 related articles for article (PubMed ID: 24780830)
1. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing
Cojutti PG; Pai MP; Tonetti T; Siniscalchi A; Viale P; Pea F
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140423. PubMed ID: 38411995
[TBL] [Abstract][Full Text] [Related]
2. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Yusuf E; Spapen H; Piérard D
J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
[TBL] [Abstract][Full Text] [Related]
3. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.
Yang H; Zhang C; Zhou Q; Wang Y; Chen L
PLoS One; 2015; 10(1):e0116769. PubMed ID: 25575030
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J;
Am J Respir Crit Care Med; 2015 Dec; 192(11):1298-305. PubMed ID: 26200166
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin-Tazobactam in Obese Patients.
Veillette JJ; Winans SA; Maskiewicz VK; Truong J; Jones RN; Forland SC
Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):385-394. PubMed ID: 33743171
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
Attivi D; Gibaud S
Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Bao H; Lv Y; Wang D; Xue J; Yan Z
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
[TBL] [Abstract][Full Text] [Related]
11. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
Intensive Crit Care Nurs; 2005 Apr; 21(2):87-93. PubMed ID: 15778072
[TBL] [Abstract][Full Text] [Related]
12. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Kim A; Sutherland CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
[TBL] [Abstract][Full Text] [Related]
13. [Piperacillin-tazobactam in continuous or expanded perfusion vs intermittent perfusion].
Acosta García H; Victoria Gil-Navarro M; Cotrina Luque J; Cisneros Herreros JM; Lepe Jiménez JA; Bautista Paloma J
Farm Hosp; 2012; 36(5):424-9. PubMed ID: 22871367
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]